- Cancer Care Team
Cancer Care Team
To deliver optimal patient outcomesProducts and Services
Cancer Type
Supplies & Tools
Scientific Focus
- Biopharma Partners
- Patients
- Education & Events
- Login
- Contact Us
Event
Corporate workshop
Wednesday, November 20th
10:00 AM – 10:50 AM
Vancouver Convention Center, Level 2, Room 208 & 209
Title: The value of internalizing FDA- authorized tumor genomic profiling solutions for tissue and liquid biopsy
Description: Clinical NGS has advanced precision oncology, enabling physicians to identify actionable biomarkers in patients to aid in therapy selection. This workshop highlights the value of internalizing FDA-cleared tissue and an FDA authorized targeted liquid biopsy tumor profiling kitted solutions with best-in-class bioinformatics to help provide greater access to cancer patients worldwide. This workshop will also showcase our new FDA de novo authorized liquid biopsy kitted solution and examine the validation data included in the FDA submission. Lastly, there will be a panel discussion of active users who will discuss their point of view on the value of internalizing these solutions.
Innovation Spotlight Stage
Thursday, November 21st
12:40 PM – 1:10 PM
Innovation Spotlight Stage #2
Title: Enabling access to genomic profiling through the FDA- authorized decentralized liquid biopsy solution, PGDx elio™ plasma focus Dx
Description: Liquid biopsy next-generation sequencing assays help guide treatment selection in cancer patients, particularly when tumor tissue is unavailable. Analytical validation an FDA authorized targeted 33-gene kitted assay, PGDx elio™ plasma focus Dx, has shown that detection of cancer-associated variants in ctDNA is highly specific, sensitive, reproducible and accurate.
Learn more about Labcorp Oncology's FDA authorized kitted tissue and liquid profiling solutions
Poster presentations:
Session Date & Time | Presenting Author | Title | Details |
Saturday, November 23 9:15AM–10:15AM PST | Sabi Pabla | Analytical validation of OmniSeq® INSIGHT whole exome sequencing assay to facilitate precision oncology through tumor-only testing in solid tumors. | Session Category: Solid Tumors Poster Board #ST021 |
Saturday, November 23 9:15AM–10:15AM PST | Sabi Pabla | Analytical validation of OmniSeq® INSIGHT whole transcriptome sequencing assay to facilitate precision oncology through tumor-only testing in solid tumors. | Session Category: Solid Tumors Poster Board #ST023 |
Saturday, November 23 9:15AM–10:15AM PST | Sabi Pabla | Validation of automated nucleic acid extraction using Covaris® Gen3 extraction methodology on the Assay-Ready Workstation. | Session Category: Technical Topics Poster Board #TT075 |
Saturday, November 23 9:15AM–10:15AM PST | Ken Valkenburg | Enabling Access to Genomic Profiling Through Decentralized Liquid Biopsy Solution PGDx elio plasma focus Dx. | Session Category: Solid Tumors Poster Board #ST093 |
Saturday, November 23 9:15AM–10:15AM PST | Michelle Green | Comprehensive genomic and immune profiling for the detection of clinically significant tumor biomarkers. | Session Category: Solid Tumors Poster Board #ST079 |
Saturday, November 23 9:15AM–10:15AM PST | [External co-author] Ashutosh Vashisht | Optimizing genomic profiling: A comparative study of chromosomal microarray (CMA) and a 505-gene next-generation sequencing (NGS) panel for homologous recombination deficiency (HRD) phenotype assessment across diverse solid tumor types using NxClinical. | Session Category: Solid Tumors Poster Board #ST125 |
Saturday, November 23 9:15AM–10:15AM PST | [External co-author] Ashutosh Vashisht | Precision Oncology: Identifying Clinically Relevant CNAs in Solid tumors using an Integrated Workflow of NGS and Bioinformatics. | Session Category: Solid Tumors Poster Board #ST129 |